Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran

Karamian, Mehdi; Bojd, M.S. Faroghi; Salehabadi, Alireza; Hemmati, Mina; Barati, Darvish Ali

doi:10.26719/2015.21.4.280

Cited by 9 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IV SSG failure rate in the current study was 29.8%, which was higher than that reported in previous studies on the antimoniate treatment of L. tropica CL (15). The failure rate among patients who received meglumine antimoniate (Glucantime) intramuscular injections (20 mg/kg for 20 days) in Iran was 9.8-12% (20,21). This may suggest that the L. tropica species in Israel are more resistant compared with those in other parts of the world, including the Middle East.…”

Section: Characteristicscontrasting

confidence: 59%

Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis

Solomon

Greenberger²,

Milner³

et al. 2022

Acta Derm Venereol

View full text Add to dashboard Cite

The effectiveness of systemic treatment for Leishmania tropica cutaneous leishmaniasis (CL) remains unclear. The purpose of the study is to evaluate the efficacy and safety of systemic treatments available against L. tropica CL. This retrospective study was performed in 114 patients. Systemic treatments included liposomal amphotericin B (L-AmB) and sodium stibogluconate (SSG). One hundred and fourteen patients underwent systemic treatment for L. tropica CL. Favorable treatment responses were recorded in 72.5% and 70.2% of the patients in the L-AmB and SSG groups, respectively; 25.3% and 46% of those in the L-AmB and SSG groups respectively, experienced at least one adverse effect. Lesions in cartilaginous areas were associated with higher treatment failure. Prior topical or systemic treatment increased the chance of future systemic treatment success. L-AmB was associated with a shorter IV treatment duration and a better safety profile. Thus, L-AmB is the treatment of choice for L. tropica CL.

show abstract

Section: Characteristicscontrasting

confidence: 59%

Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis

Solomon

Greenberger²,

Milner³

et al. 2022

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…Karamian et al (49) reported an emerging focus of ACL in Birjand county in South Khorasan province where L. tropica was identified in 89% (n = 51/57) of urban cases and 91% (n = 21/23) of ACL patients were rural dwellers. L. major was also detected in both urban and rural regions.…”

Section: Eastern Iranmentioning

confidence: 99%

The Geographical Distribution of Cutaneous Leishmaniasis Causative Agents in Iran and Its Neighboring Countries, A Review

Ghatee

Taylor

Karamian

2020

Front. Public Health

105

View full text Add to dashboard Cite

Leishmania tropica and Leishmania major are both the main cause of anthroponotic (ACL) and zoonotic cutaneous leishmaniasis (ZCL), respectively, in the Old World. Leishmania infantum and Leishmania donovani, which are important causes of visceral leishmaniasis, have also occasionally been reported in CL patients. The present study investigates the current distribution of causative species of CL in Iran and neighboring countries in the Middle East. There has been expansion of L. tropica into new urban and rural foci in Iran, with well-documented cases of visceralization, a substantial increase of CL in Syria, and the emergence of new foci and outbreaks in Turkey and Iraq, especially due to L. major. Civil war in Syria and Iraq, population movement, poverty, and climatic change play important roles in the changing CL distribution in this region. Control programs should adopt a multidisciplinary approach based on active surveillance and case finding, especially in vulnerable refugee populations, determination of hazard maps for CL hot points using GIS and other advanced technology, the free distribution of drugs, rodent control, and greater community engagement in poor and marginalized populations. Comprehensive molecular studies that could show the species and strains of Leishmania in different areas of each country can give a better view from the distribution of CL in this region.

show abstract

“…For primary sores, topical or systemic treatment approaches such as chemicals and freezing are used (Ejov and Dagne, 2014). Meglumine antimoniate (Aflatoonian et al, 2019;Karamian et al, 2015;World Health Organization, 2014) is the conventional treatment for CL. Individuals are usually resistant to reinfection from the same species after healing, and a lifelong immunity will often be produced.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment

Bamorovat

Sharifi

Aflatoonian

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran

Cited by 9 publications

References 19 publications

Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis

Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis

The Geographical Distribution of Cutaneous Leishmaniasis Causative Agents in Iran and Its Neighboring Countries, A Review

Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment

Contact Info

Product

Resources

About